{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T19:37:40Z","timestamp":1740166660034,"version":"3.37.3"},"reference-count":58,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,8,24]],"date-time":"2020-08-24T00:00:00Z","timestamp":1598227200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,8,24]],"date-time":"2020-08-24T00:00:00Z","timestamp":1598227200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Tchaikapharma High Quality Medicines Inc."}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Syst Rev"],"published-print":{"date-parts":[[2020,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n<jats:title>Background<\/jats:title>\n<jats:p>Hypertension is a disease with significant clinical and socio-economic consequences. The reduction in cardiovascular mortality and morbidity in patients treated for hypertension is directly related to the magnitude of blood pressure reduction. Diuretics have proven useful for the prevention of cardiovascular complications in addition to a long history of safety and efficacy. The main aim for this meta-analysis is to compare the efficacy of the combination of angiotensin receptor blocker (ARB) and chlorthalidone (CTLD) to the combination of ARB and hydrochlorothiazide (HCTZ) in patients with hypertension.<\/jats:p>\n<\/jats:sec><jats:sec>\n<jats:title>Methods<\/jats:title>\n<jats:p>A comprehensive literature search was conducted through electronic databases PubMed, MEDLINE, Scopus, PsyInfo, Cochrane, eLIBRARY.ru, <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"http:\/\/clinicaltrials.gov\">http:\/\/ClinicalTrials.gov<\/jats:ext-link> and <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"http:\/\/www.clinicaltrialsregister.eu\">http:\/\/www.clinicaltrialsregister.eu<\/jats:ext-link> in July 2020 to identify studies that investigate the effect of the combination of angiotensin receptor blocker with chlorthalidone or hydrochlorothiazide on the systolic and diastolic blood pressure in patients with hypertension. Changes in systolic and diastolic blood pressure (BP) expressed as a weighted mean difference (WMD) were our primary outcomes. The random-effects method was chosen as the primary analysis and results were presented with a 95% confidence interval (CI). Sensitivity analysis was performed and bias was assessed.<\/jats:p>\n<\/jats:sec><jats:sec>\n<jats:title>Results<\/jats:title>\n<jats:p>Our search returned 2745 titles. Of them, 51 full-text articles remained to be subjected to assessment. Comparisons of ARB\/HCTZ versus ARB showed changes in BP of \u22126.89 (\u22128.09, \u22125.69) mmHg for systolic BP and \u2212 3.67 (\u22124.15, \u22123.19) mmHg for diastolic BP. For the ARB\/CTLD versus ARB\/HCTZ comparison changes were \u2212 6.30 (\u22127.30, \u22125.29) mmHg for systolic BP and \u2212 3.57 (\u22124.17, 2.98) mmHg for diastolic BP.<\/jats:p>\n<\/jats:sec><jats:sec>\n<jats:title>Conclusion<\/jats:title>\n<jats:p>Our analysis suggests a small but significant favor for CTLD in blood pressure control when compared to HCTZ. We believe it should be considered as a valuable alternative for HCTZ and an option for fixed dose combinations with an ARB although further research is required.<\/jats:p>\n<\/jats:sec>","DOI":"10.1186\/s13643-020-01457-9","type":"journal-article","created":{"date-parts":[[2020,8,24]],"date-time":"2020-08-24T18:03:42Z","timestamp":1598292222000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Combining angiotensin receptor blockers with chlorthalidone or hydrochlorothiazide \u2013 which is the better alternative? A meta-analysis"],"prefix":"10.1186","volume":"9","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5786-0832","authenticated-orcid":false,"given":"Elena","family":"Filipova","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stela","family":"Dineva","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Katya","family":"Uzunova","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Velichka","family":"Pavlova","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Krassimir","family":"Kalinov","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Toni","family":"Vekov","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2020,8,24]]},"reference":[{"key":"1457_CR1","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1016\/S0140-6736(05)17741-1","volume":"365","author":"PM Kearney","year":"2005","unstructured":"Kearney PM, Whelton M, Reynolds K, Muntner P, Whelton PK, He J. Global burden of hypertension: analysis of worldwide data. Lancet. 2005;365:217\u201323.","journal-title":"Lancet"},{"key":"1457_CR2","volume-title":"World Health Organization;2013","author":"A global brief on hypertension: silent killer, global public health crisis: World Health Day","year":"2013","unstructured":"A global brief on hypertension: silent killer, global public health crisis: World Health Day. World Health Organization;2013. Geneva: World Health Organization; 2013."},{"issue":"2","key":"1457_CR3","first-page":"638","volume":"5","author":"A Petrov","year":"2018","unstructured":"Petrov A, Gatchev E, Kalinov K, Filipova E, Uzunova K, Vekov Y. Comparative bioavailability of a newly developed irbesartan 300\u2009mg containing preparation. Hosp Pharm. 2018;5(2):638\u201346.","journal-title":"Hosp Pharm"},{"issue":"6","key":"1457_CR4","doi-asserted-by":"publisher","first-page":"1206","DOI":"10.1161\/01.HYP.0000107251.49515.c2","volume":"42","author":"AV Chobanian","year":"2003","unstructured":"Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo JL Jr, et al. Seventh report of the joint National Committee on prevention, detection, evaluation, and treatment of high blood pressure. Hypertension. 2003;42(6):1206\u201352.","journal-title":"Hypertension"},{"key":"1457_CR5","doi-asserted-by":"publisher","first-page":"1903","DOI":"10.1016\/S0140-6736(02)11911-8","volume":"360","author":"S Lewington","year":"2002","unstructured":"Lewington S, Clarke R, Qizilbash N, Peto R, Collins R. Age-specific relevance of usual blood pressure to vascular mortality. Lancet. 2002;360:1903\u201313.","journal-title":"Lancet."},{"key":"1457_CR6","doi-asserted-by":"publisher","first-page":"2981","DOI":"10.1001\/jama.288.23.2981","volume":"288","author":"ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group","year":"2002","unstructured":"ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: the antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT). JAMA. 2002;288:2981\u201397.","journal-title":"JAMA."},{"key":"1457_CR7","doi-asserted-by":"publisher","first-page":"2534","DOI":"10.1001\/jama.289.19.2534","volume":"289","author":"BM Psaty","year":"2003","unstructured":"Psaty BM, Lumley T, Furberg CD, Schellenbaum G, Pahor M, Alderman, et al. Health outcomes associated with various antihypertensive therapies used as first-line agents. A network meta-analysis. JAMA. 2003;289:2534\u201344.","journal-title":"JAMA"},{"key":"1457_CR8","doi-asserted-by":"publisher","first-page":"1041","DOI":"10.1161\/HYPERTENSIONAHA.114.05021","volume":"65","author":"GC Roush","year":"2015","unstructured":"Roush GC, Ernst ME, Kostis JB, Tandon S, Sica DA. Head-to-head comparisons of hydrochlorothiazide with indapamide and chlorthalidone: antihypertensive and metabolic effects. Hypertension. 2015;65:1041\u20136.","journal-title":"Hypertension"},{"key":"1457_CR9","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1097\/HCO.0b013e3283622075","volume":"28","author":"GC Roush","year":"2013","unstructured":"Roush GC, Buddharaju V, Ernst ME. Is chlorthalidone better than hydrochlorothiazide in reducing cardiovascular events in hypertensives? Curr Opin Cardiol. 2013;28:426\u201332.","journal-title":"Curr Opin Cardiol"},{"key":"1457_CR10","doi-asserted-by":"publisher","first-page":"1110","DOI":"10.1161\/HYPERTENSIONAHA.112.191106","volume":"59","author":"GC Roush","year":"2012","unstructured":"Roush GC, Holford TR, Guddati AK. Chlorthalidone compared with hydrochlorothiazide in reducing cardiovascular events: systematic review and network meta-analyses. Hypertension. 2012;59:1110\u20137.","journal-title":"Hypertension."},{"issue":"11","key":"1457_CR11","doi-asserted-by":"publisher","first-page":"766","DOI":"10.1038\/s41371-019-0255-2","volume":"33","author":"S Dineva","year":"2019","unstructured":"Dineva S, Uzunova K, Pavlova V, Filipova E, Kalinov K, Vekov T. Comparative efficacy and safety of chlorthalidone and hydrochlorothiazide-meta-analysis. J Hum Hypertens. 2019;33(11):766\u201374. https:\/\/doi.org\/10.1038\/s41371-019-0255-2.","journal-title":"J Hum Hypertens"},{"issue":"2","key":"1457_CR12","first-page":"151","volume":"17","author":"Guidelines Subcommittee","year":"1999","unstructured":"Guidelines Subcommittee. 1999 World Health Organization-International Society of Hypertension guidelines for the management of hypertension. J Hypertens. 1999;17(2):151\u201383.","journal-title":"J Hypertens"},{"issue":"6","key":"1457_CR13","doi-asserted-by":"publisher","first-page":"1105","DOI":"10.1097\/HJH.0b013e3281fc975a","volume":"25","author":"G Mancia","year":"2007","unstructured":"Mancia G, De Backer G, Dominiczak A, Cifkova R, Fagard R, Germano G, et al. 2007 guidelines for the management of arterial hypertension: the task force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens. 2007;25(6):1105\u201387.","journal-title":"J Hypertens"},{"key":"1457_CR14","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1001\/archinte.1993.00410020010002","volume":"153","author":"Joint National Committee on Detection, Evaluation and Treatment of High Blood Pressure","year":"1993","unstructured":"Joint National Committee on Detection, Evaluation and Treatment of High Blood Pressure. The fifth report of the joint National Committee on detection, evaluation and treatment of high blood pressure (JNCV). Arch Intern Med. 1993;153:154\u201383.","journal-title":"Arch Intern Med"},{"key":"1457_CR15","doi-asserted-by":"publisher","first-page":"1969","DOI":"10.1001\/archinte.1996.00440160081011","volume":"156","author":"M Epstein","year":"1996","unstructured":"Epstein M, Bakris G. Newer approaches to antihypertensive therapy. Use of fixed dose combination therapy. Arch Intern Med. 1996;156:1969\u201378.","journal-title":"Arch Intern Med"},{"key":"1457_CR16","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1001\/jama.2013.284427","volume":"311","author":"PA James","year":"2014","unstructured":"James PA, Oparil S, Carter BL, Cushman WC, Dennison-Himmelfarb C, Handler J, et al. 2014 evidence-based guideline for the management of high blood pressure in adults: report from the panel members appointed to the eighth joint National Committee (JNC 8). JAMA. 2014;311:507\u201320.","journal-title":"JAMA."},{"issue":"2","key":"1457_CR17","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1111\/j.1751-7176.2008.07439.x","volume":"10","author":"MR Weir","year":"2008","unstructured":"Weir MR, Bakris GL. Combination therapy with renin-angiotensin-aldosterone receptor blockers for hypertension: how far have we come? J Clin Hypertens (Greenwich). 2008;10(2):146\u201352.","journal-title":"J Clin Hypertens (Greenwich)"},{"key":"1457_CR18","doi-asserted-by":"publisher","first-page":"885","DOI":"10.2146\/ajhp090419","volume":"67","author":"N Sood","year":"2010","unstructured":"Sood N, Reinhart KM, Baker WL. Combination therapy for the management of hypertension: a review of the evidence. Am J Health Syst Pharm. 2010;67:885\u201394.","journal-title":"Am J Health Syst Pharm"},{"issue":"1","key":"1457_CR19","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1080\/08037050510008832","volume":"14","author":"A Mimran","year":"2005","unstructured":"Mimran A, Weir MR. Angiotensin-receptor blockers and diuretics--advantages of combination. Blood Press. 2005;14(1):6\u201311.","journal-title":"Blood Press"},{"issue":"9","key":"1457_CR20","doi-asserted-by":"publisher","first-page":"581","DOI":"10.2165\/11536710-000000000-00000","volume":"30","author":"R Fogari","year":"2010","unstructured":"Fogari R, Taddei S, Holm-Bentzen M, Baszak J, Melani L, Schumacher K. Efficacy and safety of olmesartan medoxomil 40\u2009mg\/hydrochlorothiazide 12.5\u2009mg combination therapy versus olmesartan medoxomil 40\u2009mg monotherapy in patients with moderate to severe hypertension: a randomized, double-blind, parallel-group, multicentre, mult. Clin. Drug Investig. 2010;30(9):581\u201397. https:\/\/doi.org\/10.2165\/11536710-000000000-00000.","journal-title":"Drug Investig"},{"issue":"12","key":"1457_CR21","doi-asserted-by":"publisher","first-page":"861","DOI":"10.1038\/sj.jhh.1000718","volume":"12","author":"JR Benz","year":"1998","unstructured":"Benz JR, Black HR, Graff A, Reed A, Fitzsimmons S, Shi Y. Valsartan and hydrochlorothiazide in patients with essential hypertension. A multiple dose, double-blind, placebo controlled trial comparing combination therapy with monotherapy. J Hum Hypertens. 1998;12(12):861\u20136. https:\/\/doi.org\/10.1038\/sj.jhh.1000718.","journal-title":"J Hum Hypertens"},{"issue":"5","key":"1457_CR22","doi-asserted-by":"publisher","first-page":"293","DOI":"10.2165\/00044011-200929050-00002","volume":"29","author":"I Edes","year":"2009","unstructured":"Edes I, Group MS. Combination therapy with candesartan cilexetil 32\u2009mg and hydrochlorothiazide 25\u2009mg provides the full additive antihypertensive effect of the components: a randomized, double-blind, parallel-group study in primary care. Clin Drug Investig. 2009;29(5):293\u2013304.","journal-title":"Clin Drug Investig"},{"issue":"1","key":"1457_CR23","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1038\/hr.2012.143","volume":"36","author":"BJ Kwon","year":"2013","unstructured":"Kwon BJ, Jang SW, Choi KY, Kim DB, Cho EJ, Ihm SH, et al. Comparison of the efficacy between hydrochlorothiazide and chlorthalidone on central aortic pressure when added on to candesartan in treatment-na\u00efve patients of hypertension. Hypertens Res. 2013;36(1):79\u201384. https:\/\/doi.org\/10.1038\/hr.2012.143.","journal-title":"Hypertens Res"},{"issue":"2","key":"1457_CR24","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1097\/00045391-200203000-00005","volume":"9","author":"Y Lacourciere","year":"2002","unstructured":"Lacourciere Y, Martin K. Comparison of a fixed-dose combination of 40\u2009mg telmisartan plus 12.5\u2009mg hydrochlorothiazide with 40\u2009mg telmisartan in the control of mild to moderate hypertension. Am J Ther. 2002;9(2):111\u20137.","journal-title":"Am J Ther"},{"issue":"11","key":"1457_CR25","doi-asserted-by":"publisher","first-page":"763","DOI":"10.1038\/sj.jhh.1001267","volume":"15","author":"Y Lacourci\u00e8re","year":"2001","unstructured":"Lacourci\u00e8re Y, Tytus R, O\u2019Keefe D, Lenis J, Orchard R, Martin K. Efficacy and tolerability of a fixed-dose combination of telmisartan plus hydrochlorothiazide in patients uncontrolled with telmisartan monotherapy. J Hum Hypertens. 2001;15(11):763\u201370. https:\/\/doi.org\/10.1038\/sj.jhh.1001267.","journal-title":"J Hum Hypertens"},{"issue":"7","key":"1457_CR26","doi-asserted-by":"publisher","first-page":"1013","DOI":"10.1016\/j.clinthera.2005.07.010","volume":"27","author":"Y Lacourci\u00e8re","year":"2005","unstructured":"Lacourci\u00e8re Y, Poirier L, Hebert D, Assouline L, Stolt P, Rehel B, et al. Antihypertensive efficacy and tolerability of two fixed-dose combinations of valsartan and hydrochlorothiazide compared with valsartan monotherapy in patients with stage 2 or 3 systolic hypertension: an 8-week, randomized, double-blind, parallel-group T. Clin Ther. 2005;27(7):1013\u201321.","journal-title":"Clin Ther"},{"issue":"2","key":"1457_CR27","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1080\/10641960802621259","volume":"31","author":"S Makita","year":"2009","unstructured":"Makita S, Abiko A, Naganuma Y, Tamada M, Nakamura M. Efficacy of low-dose hydrochlorothiazide in combination with telmisartan on early morning blood pressure in uncontrolled hypertensive patients. Clin Exp Hypertens. 2009;31(2):105\u201315. https:\/\/doi.org\/10.1080\/10641960802621259.","journal-title":"Clin Exp Hypertens"},{"key":"1457_CR28","doi-asserted-by":"publisher","first-page":"2847","DOI":"10.2147\/DDDT.S82098","volume":"9","author":"MY Rhee","year":"2015","unstructured":"Rhee MY, Baek SH, Kim W, Park CG, Park SW, Oh BH, et al. Efficacy of fimasartan\/hydrochlorothiazide combination in hypertensive patients inadequately controlled by fimasartan monotherapy. Drug Des Devel Ther. 2015;9:2847\u201354. https:\/\/doi.org\/10.2147\/DDDT.S82098.","journal-title":"Drug Des Devel Ther"},{"issue":"3","key":"1457_CR29","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1038\/sj.jhh.1001317","volume":"16","author":"A Sachse","year":"2002","unstructured":"Sachse A, Verboom CN, J\u00e4ger B. Efficacy of eprosartan in combination with HCTZ in patients with essential hypertension. J Hum Hypertens. 2002;16(3):169\u201376. https:\/\/doi.org\/10.1038\/sj.jhh.1001317.","journal-title":"J Hum Hypertens"},{"key":"1457_CR30","doi-asserted-by":"publisher","first-page":"2022","DOI":"10.1016\/S0140-6736(04)16451-9","volume":"363","author":"S Julius","year":"2004","unstructured":"Julius S, Kjeldsen SE, Weber M, Brunner HR, Ekman S, Hansson L, et al. VALUE trial group, outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial. Lancet. 2004;363:2022\u201331.","journal-title":"Lancet."},{"issue":"7414","key":"1457_CR31","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1136\/bmj.327.7414.557","volume":"327","author":"JP Higgins","year":"2003","unstructured":"Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ. 2003;327(7414):557\u201360. https:\/\/doi.org\/10.1136\/bmj.327.7414.557.","journal-title":"BMJ."},{"key":"1457_CR32","doi-asserted-by":"publisher","first-page":"278","DOI":"10.1001\/archinte.1996.00440030072009","volume":"156","author":"JH Mackay","year":"1996","unstructured":"Mackay JH, Arcuri KE, Goldberg AI, Snapinn SM, Sweet CS. Losartan and low-dose hydrochlorothiazide in patients with essential hypertension. Arch Intern Med. 1996;156:278\u201385.","journal-title":"Arch Intern Med"},{"issue":"5","key":"1457_CR33","doi-asserted-by":"publisher","first-page":"284","DOI":"10.1111\/j.1751-7176.2012.00616.x","volume":"14","author":"D Sica","year":"2012","unstructured":"Sica D, Bakris GL, White WB, Weber MA, Cushman WC, Huang P, et al. Blood pressure-lowering efficacy of the fixed-dose combination of azilsartan medoxomil and chlorthalidone: a factorial study. J Clin Hypertens. 2012;14(5):284\u201392. https:\/\/doi.org\/10.1111\/j.1751-7176.2012.00616.x.","journal-title":"J Clin Hypertens"},{"issue":"2","key":"1457_CR34","doi-asserted-by":"publisher","first-page":"310","DOI":"10.1161\/HYPERTENSIONAHA.111.188284","volume":"60","author":"WC Cushman","year":"2012","unstructured":"Cushman WC, Bakris GL, White WB, Weber MA, Sica D, Roberts A, et al. Azilsartan medoxomil plus chlorthalidone reduces blood pressure more effectively than olmesartan plus hydrochlorothiazide in stage 2 systolic hypertension. Hypertension. 2012;60(2):310\u20138. https:\/\/doi.org\/10.1161\/HYPERTENSIONAHA.111.188284.","journal-title":"Hypertension."},{"issue":"4","key":"1457_CR35","doi-asserted-by":"publisher","first-page":"947","DOI":"10.1097\/HJH.0000000000001647","volume":"36","author":"WC Cushman","year":"2018","unstructured":"Cushman WC, Bakris GL, White WB, Weber MA, Sica D, Roberts A, et al. A randomized titrate-to-target study comparing fixed-dose combinations of azilsartanmedoxomil and chlorthalidone with olmesartan and hydrochlorothiazide in stage-2 systolic hypertension. J Hypertens. 2018;36(4):947\u201356. https:\/\/doi.org\/10.1097\/HJH.0000000000001647.","journal-title":"J Hypertens"},{"issue":"9","key":"1457_CR36","doi-asserted-by":"publisher","first-page":"874","DOI":"10.1111\/jch.13009","volume":"19","author":"JM Neutel","year":"2017","unstructured":"Neutel JM, Cushman WC, Lloyd E, Barger B, Handley A. Comparison of long-term safety of fixed-dose combinations azilsartan medoxomil\/chlorthalidone vs olmesartan medoxomil\/hydrochlorothiazide. J Clin Hypertens. 2017;19(9):874\u201383. https:\/\/doi.org\/10.1111\/jch.13009.","journal-title":"J Clin Hypertens"},{"issue":"6","key":"1457_CR37","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1007\/s11906-013-0401-0","volume":"15","author":"Z Gaciong","year":"2013","unstructured":"Gaciong Z, Si\u0144ski M, Lewandowski J. Blood pressure control and primary prevention of stroke: summary of the recent clinical trial data and meta-analyses. Curr Hypertens Rep. 2013;15(6):559\u201374. https:\/\/doi.org\/10.1007\/s11906-013-0401-0 PMID: 24158454; PMCID: PMC3838588.","journal-title":"Curr Hypertens Rep"},{"issue":"8","key":"1457_CR38","doi-asserted-by":"publisher","first-page":"921","DOI":"10.1007\/s11606-017-4000-7","volume":"32","author":"P Makai","year":"2017","unstructured":"Makai P, IntHout J, Deinum J, Jenniskens K, Wilt GJV. A network meta-analysis of clinical management strategies for treatment-resistant hypertension: making optimal use of the evidence. J Gen Intern Med. 2017;32(8):921\u201330. https:\/\/doi.org\/10.1007\/s11606-017-4000-7 Epub 2017 Mar 8. PMID: 28275946; PMCID: PMC5515781.","journal-title":"J Gen Intern Med"},{"key":"1457_CR39","doi-asserted-by":"publisher","first-page":"324","DOI":"10.1111\/j.1527-5299.2003.03269.x","volume":"9","author":"AA Taylor","year":"2003","unstructured":"Taylor AA, Shoheiber O. Adherence to antihypertensive therapy with fixed-dose amlodipine besylate\/benazepril HCl versus comparable component-based therapy. Congest Heart Fail. 2003;9:324\u201332.","journal-title":"Congest Heart Fail"},{"issue":"9","key":"1457_CR40","doi-asserted-by":"publisher","first-page":"677","DOI":"10.1111\/j.1751-7176.2011.00518.x","volume":"13","author":"AA Taylor","year":"2011","unstructured":"Taylor AA, Siragy H, Nesbitt S. Angiotensin receptor blockers: pharmacology, efficacy, and safety. J Clin Hypertens (Greenwich). 2011;13(9):677\u201386. https:\/\/doi.org\/10.1111\/j.1751-7176.2011.00518.x Epub 2011 Jul 27.","journal-title":"J Clin Hypertens (Greenwich)"},{"issue":"Suppl 1","key":"1457_CR41","first-page":"162","volume":"13","author":"WC Cushman","year":"2011","unstructured":"Cushman WC, Bakris GL, White WB, Weber MA, Sica D, Roberts A, et al. Efficacy and safety of azilsartan medoximil\/chlorthalidone vs olmesartan\/HCTZ combinations in stage 2 systolic hypertension. J Clin Hypertens (Greenwich). 2011;13(Suppl 1):162.","journal-title":"J Clin Hypertens (Greenwich)"},{"key":"1457_CR42","volume-title":"Hypertension in adults: diagnosis and management","author":"National Guideline Centre (UK)","year":"2019","unstructured":"National Guideline Centre (UK). Hypertension in adults: diagnosis and management. London: National Institute for Health and Care Excellence (UK); 2019. PMID: 31577399."},{"issue":"1","key":"1457_CR43","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1111\/jch.12624","volume":"18","author":"BN Mukete","year":"2016","unstructured":"Mukete BN, Ferdinand KC. Polypharmacy in older adults with hypertension: a comprehensive review. J Clin Hypertens (Greenwich). 2016;18(1):10\u20138. https:\/\/doi.org\/10.1111\/jch.12624 Epub 2015 Jul 27. PMID: 26215211.","journal-title":"J Clin Hypertens (Greenwich)"},{"issue":"1","key":"1457_CR44","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1186\/s12913-019-3942-3","volume":"19","author":"M Stuhec","year":"2019","unstructured":"Stuhec M, Gorenc K, Zelko E. Evaluation of a collaborative care approach between general practitioners and clinical pharmacists in primary care community settings in elderly patients on polypharmacy in Slovenia: a cohort retrospective study reveals positive evidence for implementation. BMC Health Serv Res. 2019;19(1):118. https:\/\/doi.org\/10.1186\/s12913-019-3942-3 PMID: 30760276; PMCID: PMC6375190.","journal-title":"BMC Health Serv Res"},{"issue":"4","key":"1457_CR45","doi-asserted-by":"publisher","first-page":"932","DOI":"10.1007\/s11096-019-00855-x","volume":"41","author":"M \u0160tuhec","year":"2019","unstructured":"\u0160tuhec M, Poto\u010din I, Stepan D, U\u0161aj L, Petek \u0160ter M, et al. Potential drug interactions with antibacterials in long-term care facilities analyzed by two interaction checkers. Int J Clin Pharm. 2019;41(4):932\u20138. https:\/\/doi.org\/10.1007\/s11096-019-00855-x Epub 2019 Jun 6. PMID: 31172409.","journal-title":"Int J Clin Pharm"},{"issue":"3","key":"1457_CR46","doi-asserted-by":"publisher","first-page":"461","DOI":"10.33549\/physiolres.933120","volume":"65","author":"NC Hess","year":"2016","unstructured":"Hess NC, Carlson DJ, Inder JD, Jesulola E, McFarlane JR, Smart NA. Clinically meaningful blood pressure reductions with low intensity isometric handgrip exercise. A randomized trial. Physiol Res. 2016;65(3):461\u20138. https:\/\/doi.org\/10.33549\/physiolres.933120 Epub 2016 Apr 12. PMID: 27070747.","journal-title":"Physiol Res"},{"issue":"3","key":"1457_CR47","doi-asserted-by":"publisher","first-page":"657","DOI":"10.1517\/14656566.5.3.657","volume":"5","author":"SG Chrysant","year":"2004","unstructured":"Chrysant SG, Chrysant GS. Antihypertensive efficacy of olmesartan medoxomil alone and in combination with hydrochlorothiazide. Expert Opin Pharmacother. 2004;5(3):657\u201367.","journal-title":"Expert Opin Pharmacother"},{"issue":"3","key":"1457_CR48","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1586\/14779072.1.3.335","volume":"1","author":"SG Chrysant","year":"2003","unstructured":"Chrysant SG. Fixed combination therapy of hypertension: focus on valsartan\/hydrochlorothiazide combination (Diovan\/HCT). Expert Rev Cardiovasc Ther. 2003;1(3):335\u201343.","journal-title":"Expert Rev Cardiovasc Ther"},{"issue":"4","key":"1457_CR49","doi-asserted-by":"publisher","first-page":"366","DOI":"10.1177\/147323000203000402","volume":"30","author":"Y Lacourci\u00e8re","year":"2002","unstructured":"Lacourci\u00e8re Y. A new fixed-dose combination for added blood pressure control: telmisartan plus hydrochlorothiazide. J Int Med Res. 2002;30(4):366\u201379.","journal-title":"J Int Med Res"},{"issue":"3","key":"1457_CR50","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1586\/14779072.3.3.375","volume":"3","author":"M Maillard","year":"2005","unstructured":"Maillard M, Burnier M. Telmisartan\/hydrochlorothiazide: a new fixed dose combination. Expert Rev Cardiovasc Ther. 2005;3(3):375\u201386.","journal-title":"Expert Rev Cardiovasc Ther"},{"issue":"5","key":"1457_CR51","doi-asserted-by":"publisher","first-page":"787","DOI":"10.2165\/00003495-200262050-00006","volume":"62","author":"EB Melian","year":"2002","unstructured":"Melian EB, Jarvis B. Candesartan cilexetil plus hydrochlorothiazide combination: a review of its use in hypertension. Drugs. 2002;62(5):787\u2013816.","journal-title":"Drugs."},{"issue":"10","key":"1457_CR52","doi-asserted-by":"publisher","first-page":"569","DOI":"10.1111\/j.1524-6175.2004.02632.x","volume":"6","author":"CV Ram","year":"2004","unstructured":"Ram CV. Antihypertensive efficacy of angiotensin receptor blockers in combination with hydrochlorothiazide: a review of the factorial-design studies. J Clin Hypertens (Greenwich). 2004 Oct;6(10):569\u201377.","journal-title":"J Clin Hypertens (Greenwich)"},{"issue":"5","key":"1457_CR53","doi-asserted-by":"publisher","first-page":"1616","DOI":"10.1161\/01.CIR.82.5.1616","volume":"82","author":"Multiple Risk Factor Intervention Trial Research Group","year":"1990","unstructured":"Multiple Risk Factor Intervention Trial Research Group. Mortality after 10 1\/2\u2009years for hypertensive participants in the multiple risk factor intervention trial. Circulation. 1990;82(5):1616\u201328.","journal-title":"Circulation"},{"key":"1457_CR54","doi-asserted-by":"publisher","first-page":"689","DOI":"10.1161\/HYPERTENSIONAHA.110.161505","volume":"57","author":"M Dorsch","year":"2011","unstructured":"Dorsch M, Gillespie B, Erikson S. Chlorthalidone reduces cardiovascular events compared with hydrochlorothiazide: a retrospective cohort analysis. Hypertension. 2011;57:689\u201394.","journal-title":"Hypertension"},{"key":"1457_CR55","doi-asserted-by":"publisher","first-page":"447","DOI":"10.7326\/0003-4819-158-6-201303190-00004","volume":"158","author":"IA Dhalla","year":"2013","unstructured":"Dhalla IA, Gomes T, Yao Z, Nagge J, Persaud N, Hellings C, et al. Chlorthalidone versus hydrochlorothiazide for the treatment of hypertension in older adults: a population-based cohort study. Ann Intern Med. 2013;158:447\u201355.","journal-title":"Ann Intern Med"},{"key":"1457_CR56","doi-asserted-by":"publisher","first-page":"352","DOI":"10.1161\/01.HYP.0000203309.07140.d3","volume":"47","author":"M Ernst","year":"2006","unstructured":"Ernst M, Carter B, Goerdt C. Comparative antihypertensive effects of hydrochlorothiazide and chlorthalidone on ambulatory and office blood pressure. Hypertension. 2006;47:352\u20138.","journal-title":"Hypertension"},{"issue":"4","key":"1457_CR57","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1016\/j.jacc.2015.10.083","volume":"67","author":"AK Pareek","year":"2016","unstructured":"Pareek AK, Messerli FH, Chandurkar NB, Dharmadhikari SK, Godbole AV, Kshirsagar PP, et al. Efficacy of lowdose chlorthalidone and hydrochlorothiazide as assessed by 24-h ambulatory blood pressure monitoring. JACC. 2016;67(4):379\u201389.","journal-title":"JACC"},{"key":"1457_CR58","doi-asserted-by":"publisher","first-page":"1104","DOI":"10.1161\/HYPERTENSIONAHA.111.190637","volume":"59","author":"MA Peterzan","year":"2012","unstructured":"Peterzan MA, Hardy R, Chaturvedi N, Hughes AD. Meta-analysis of dose response relationships for hydrochlorothiazide, chlorthalidone, and bendroflumethiazide on blood pressure, serum potassium, and urate. Hypertension. 2012;59:1104\u20139.","journal-title":"Hypertension"}],"container-title":["Systematic Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13643-020-01457-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13643-020-01457-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13643-020-01457-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,8,24]],"date-time":"2021-08-24T00:51:57Z","timestamp":1629766317000},"score":1,"resource":{"primary":{"URL":"https:\/\/systematicreviewsjournal.biomedcentral.com\/articles\/10.1186\/s13643-020-01457-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,8,24]]},"references-count":58,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["1457"],"URL":"https:\/\/doi.org\/10.1186\/s13643-020-01457-9","relation":{},"ISSN":["2046-4053"],"issn-type":[{"type":"electronic","value":"2046-4053"}],"subject":[],"published":{"date-parts":[[2020,8,24]]},"assertion":[{"value":"6 February 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 August 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 August 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Not applicable.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"SD, VP, KU, and EF are employees of Tchaikapharma High Quality Medicines Inc. The other authors report no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"195"}}